<DOC>
	<DOCNO>NCT02320669</DOCNO>
	<brief_summary>This study determine safety efficacy liothyronine sodium/triiodothyronine ( Triostat ) , synthetic thyroid hormone , give infant congenital heart disease cardiopulmonary bypass surgery . Funding Source - FDA OOPD .</brief_summary>
	<brief_title>Phase 3 Triiodothyronine Supplementation Infants After Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<criteria>1 . Informed consent obtain 2 . Male female patient &lt; 5 month ( 152 day ) age 3 . Patients undergo cardiopulmonary bypass 1 . Known thyroid disease ( Down Syndrome exclusion criterion unless patient thyroid disease ) 2 . Trisomy 13 18 3 . Prolonged preoperative ventilator support would impact cardiac surgery ( Lung disease : bronchopulmonary dysplasia , hypoplastic lung associate diaphragmatic hernia ) 4 . Any condition determine PI cause prolonged ventilator support unlikely respond favorably cardiac surgery 5 . Prior participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>